Promising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy Rating

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on NextCure (NXTC – Research Report) today and set a price target of $8.00.

Emily Bodnar’s rating is based on the promising preclinical data of LNCB74, a novel antibody-drug conjugate (ADC) developed by NextCure, which has demonstrated significant anti-tumor activity across various cancer types. The drug’s mechanism involves a targeted approach to cancer therapy, where the ADC is designed to selectively bind to B7-H4, a protein commonly found on several solid tumors, including breast, ovarian, and endometrial cancers. The efficacy of LNCB74 is underscored by its potent binding affinity and its selective cytotoxicity, which has shown impressive results in reducing tumor volumes even in cancers with low B7-H4 expression.
Furthermore, the safety profile of LNCB74 appears favorable due to its innovative design, which includes a specialized linker technology enhancing the drug’s stability and targeted release within tumor cells, combined with a modified Fc region to minimize unintended immune cell uptake and toxicity. These features collectively support the drug’s potential as a therapeutic agent, and the data suggests that LNCB74 could effectively treat a range of breast cancer subtypes, including those with varying levels of B7-H4 expression. This breadth of activity, along with the drug’s design optimizations, contributes to the Buy rating as it indicates a strong prospect for clinical development and future market success.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

NextCure (NXTC) Company Description:

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.